Overview

Investigator-initiated Clinical Trial of MIKE-1

Status:
Recruiting

Trial end date:
2025-04-30

Target enrollment:

Participant gender:

Summary

To evaluate the safety and tolerability of Am80（Generic name: Tamibarotene, Development code: MIKE-1） in combination with gemcitabine (GEM) and nab-paclitaxel (nab-PTX) in patients with unresectable pancreatic cancer and to determine the recommended dose. Efficacy will also be exploratively investigated.

Phase:

Phase 1/Phase 2

Details

Lead Sponsor:

Nagoya University

Collaborator:

Japan Agency for Medical Research and Development